Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gemfibrozil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA known ✓ | Q07869 | 9/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 2/20 | 1.00 |
| ▸ | TTR | P02766 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | PPARG | P37231 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 1.00 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.59 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.57 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gemfibrozil SCHEMBL1880616 | 1.00 | PPARA (1.00) | PPARATSHRCYP2C9CYP2C8TTR | |
| Gemfibrozil SCHEMBL4813 | 1.00 | PPARA (1.00) | PPARATSHRCYP2C9CYP2C8TTR | |
| Gemfibrozil SCHEMBL20770039 | 1.00 | PPARA (1.00) | PPARATSHRCYP2C9CYP2C8TTR | |
| Gemfibrozil SCHEMBL457931 | 0.99 | PPARA (0.97) | PPARATSHRCYP2C9CYP2C8TTR | |
| Gemfibrozil SCHEMBL21052128 | 0.99 | PPARA (0.97) | PPARATSHRCYP2C9CYP2C8TTR | |
| Gemfibrozil SCHEMBL10542601 | 0.99 | PPARA (0.97) | PPARATSHRCYP2C9CYP2C8TTR | |
| Gemfibrozil SCHEMBL6033508 | 0.95 | PPARA (0.90) | PPARATSHRCYP2C9CYP2C8TTR | |
| SCHEMBL21992001 | 0.93 | PPARA (0.86) | PPARATSHRCYP2C9CYP2C8TTR | |
| SCHEMBL30504804 | 0.88 | PPARA (0.79) | PPARATSHRCYP2C9CYP2C8TTR | |
| SCHEMBL9481043 | 0.88 | PPARA (0.79) | PPARATSHRCYP2C9CYP2C8TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3787631-B1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | UNIV EMORY (US) | 2025-09-10 | — | — | EP | claimed |
| US-20250051430-A1 | NEUTRALIZATION OF ACYL-COA BINDING PROTEIN CONFERS AUTOPHAGY-DEPENDENT ORGAN PROTECTION | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-02-13 | — | — | US | claimed |
| EP-4475883-A1 | NEUTRALIZATION OF ACYL-COA BINDING PROTEIN CONFERS AUTOPHAGY-DEPENDENT ORGAN PROTECTION | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2024-12-18 | — | — | EP | claimed |
| WO-2023152637-A1 | NEUTRALIZATION OF ACYL-COA BINDING PROTEIN CONFERS AUTOPHAGY-DEPENDENT ORGAN PROTECTION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2023-08-17 | — | — | WO | claimed |
| EP-4165233-A1 | HYBRID ELECTRODIALYSIS AND ELECTROLYSIS SYSTEMS AND PROCESSES | Pani Clean, Inc. (US) | 2023-04-19 | — | — | EP | claimed |
| EP-3955912-A1 | ANTI-HYPERTENSIVE AND CHOLESTEROL-LOWERING FIXED-DOSE COMBINATION AND METHOD OF MANUFACTURE | Cardiopharma, Inc. (US) | 2022-02-23 | — | — | EP | claimed |
| EP-4687900-A2 | COMBINATION TREATMENT FOR OVARIAN CANCER | The Johns Hopkins University (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4673152-A2 | COMBINATIONS FOR TREATMENT OF PARKINSON'S DISEASE AND OTHER PRIMARY AND SECONDARY PARKINSONIAN DISORDERS | Kenai Therapeutics Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20250381158-A1 | MAGNESIUM COMPOSITIONS AND USES THEREOF FOR NEUROLOGICAL DISORDERS | NEUROCENTRIA INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250339445-A1 | Modulators of Orphan Nuclear Receptors for Treating Pancreatitis, Glioblastoma, Sarcopenia and Stroke | UNIV EMORY (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250312396-A1 | Control of Cellular Redox Levels | MCKENNA ELIZABETH (US) | 2025-10-09 | — | — | US | disclosed |
| EP-3787631-B1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | UNIV EMORY (US) | 2025-09-10 | — | — | EP | disclosed |
| US-12371354-B2 | Method of facilitating growth of specific microorganisms | GROSS-WEN TECHNOLOGIES, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-11351142-B2 | Composition and method for treating neuronal ceroid lipofuscinosis | RUSH UNIVERSITY MEDICAL CENTER (US) | 2022-06-07 | — | — | US | disclosed |
| US-11339070-B2 | Targeted pollutant release in microorganisms | GROSS-WEN TECHNOLOGIES, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| WO-2022098641-A1 | ENHANCED UPTAKE TRANSMUCOSAL DRUG DELIVERY COMPOSITIONS AND METHODS OF USE | PADAGIS ISRAEL PHARMACEUTICALS LTD. (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022094435-A1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR TREATING PANCREATITIS, GLIOBLASTOMA, SARCOPENIA AND STROKE | EMORY UNIVERSITY (US) | 2022-05-05 | — | — | WO | disclosed |
| CN-114377136-A | Combined medicine for treating hyperlipemia and its use | 中国医学科学院药物研究所 | 2022-04-22 | — | — | CN | disclosed |
| US-20220098197-A1 | SALTS OF HETEROCYCLIC COMPOUND AND USE THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2022-03-31 | — | — | US | disclosed |
| EP-3955912-A1 | ANTI-HYPERTENSIVE AND CHOLESTEROL-LOWERING FIXED-DOSE COMBINATION AND METHOD OF MANUFACTURE | Cardiopharma, Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098197-A1 | SALTS OF HETEROCYCLIC COMPOUND AND USE THEREOF | CXCL10, CXCL8, LITAF | PPARA 457/4885TSHR 3505/4885CYP2C9 1679/4885 |
| US-20250381158-A1 | MAGNESIUM COMPOSITIONS AND USES THEREOF FOR NEUROLOGICAL DISORDERS | MAPT, PYGB, ACHE | PPARA 3593/4885TSHR 4070/4885CYP2C9 2332/4885 |
| US-20250339445-A1 | Modulators of Orphan Nuclear Receptors for Treating Pancreatitis, Glioblastoma, Sarcopenia and Stroke | RXRA, RXRG, RXRB | PPARA 11/4885TSHR 68/4885CYP2C9 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.